Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504669 · ClinicalTrials.gov registry record · Phase 1
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT04504669 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 60 participants.
The verdict
NCT04504669, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors
Interventions
- BIOLOGICAL Durvalumab
- DRUG AZD8701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2024-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04504669
The ClinicalTrials.gov registry entry for NCT04504669 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT04504669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04504669 about?
NCT04504669 is a clinical study titled "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours". The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors
What is the current status of trial NCT04504669?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2020-08-18. Estimated completion is 2024-10-07.
What interventions are being tested in trial NCT04504669?
The interventions under investigation include: Durvalumab (BIOLOGICAL), AZD8701 (DRUG).
Who is sponsoring clinical trial NCT04504669?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.